{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Rova-T', 'Rovalpituzumab tesirine', 'RPTD', 'Recommended Phase 2 dose', 'SAE', 'Serious adverse event', 'SAP', 'Statistical analysis plan', 'SC-DR002', 'DNA cross-linking agent also known as D6.5', 'SC16', 'Humanized DLL3-specific IgG1 antibody', 'SCLC', 'Small cell lung cancer', 'SD', 'Stable disease', 'SIADH', 'Syndrome of Inappropriate Anti-Diuretic Hormone', 'SMPC', 'Summary of product characteristics', 'SPF', 'Sun protection factor', 'SUSAR', 'Suspected Unexpected Serious Adverse Reactions', 'TBL', 'Total bilirubin', 'TEAE', 'Treatment-emergent adverse event', 'TIC', 'Tumor-initiating cells', 'TNM', 'Tumor, node, metastases', 'TTP', 'Time to progression', 'ULN', 'Upper limit of normal', 'VA', 'Veterans Administration', 'VEGF', 'Vascular endothelial growth factor', 'WHODRUG', 'World Health Organization Drug (Dictionary)', 'WOCBP', 'Women of childbearing potential', '20']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '2.0', 'Table of Contents', '1.0', 'Title Page', '1', '1.1', 'Protocol Amendment: Summary of Changes', '2', '1.2', 'Synopsis', '10', '1.3', 'List of Abbreviations and Definition of Terms', '17', '2.0', 'Table of Contents', '21', '3.0', 'Introduction', '26', '3.1', 'Small Cell Lung Cancer', '26', '3.2', 'Delta-Like Protein 3', '26', '3.3', 'Rovalpituzumab Tesirine', '27', '3.4', 'Differences Statement', '29', '3.5', 'Benefits and Risks', '29', '4.0', 'Study Objectives', '30', '5.0', 'Investigational Plan', '32', '5.1', 'Overall Study Design and Plan: Description', '32', '5.2', 'Selection of Study Population', '33', '5.2.1', 'Inclusion Criteria', '34', '5.2.2', 'Exclusion Criteria', '36', '5.2.3', 'Prior and Concomitant Therapy', '38', '5.2.3.1', 'Prior Therapy', '38', '5.2.3.2', 'Concomitant Therapy', '39', '5.2.3.2.1', 'Allowed Concomitant Therapy', '39', '5.2.3.3', 'Prohibited Therapy', '41', '5.2.4', 'Contraception Recommendations', '41', '5.3', 'Efficacy, Pharmacokinetic, Biomarker, Pharmacogenetic and', 'Safety Assessments/Variables', '42', '5.3.1', 'Efficacy and Safety Measurements Assessed and Flow Chart', '42', '5.3.1.1', 'Study Procedures', '43', '5.3.1.2', 'Collection and Handling of Biomarker and Optional Exploratory', 'Research Samples', '55', '5.3.2', 'Drug Concentration Measurements', '58', '5.3.2.1', 'Collection of Samples for Analysis', '58', '21']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '5.3.2.2', 'Handling/Processing of Samples', '58', '5.3.2.3', 'Disposition of Samples', '58', '5.3.2.4', 'Measurement Methods', '59', '5.3.3', 'Efficacy Variables', '59', '5.3.3.1', 'Definition of Disease Progression', '59', '5.3.3.2', 'Primary Variables', '59', '5.3.3.3', 'Secondary Variables', '60', '5.3.3.4', 'Exploratory Variables', '60', '5.3.4', 'Safety Variables', '60', '5.3.5', 'Pharmacokinetic Variables', '61', '5.3.6', 'Biomarker and/or Optional Exploratory Research Variables', '61', '5.4', 'Removal of Subjects from Therapy or Assessment', '62', '5.4.1', 'Discontinuation of Individual Subjects', '63', '5.4.2', 'Discontinuation of Entire Study', '64', '5.5', 'Treatments', '64', '5.5.1', 'Treatments Administered', '64', '5.5.2', 'Identity of Investigational Product(s)', '65', '5.5.2.1', 'Packaging and Labeling', '65', '5.5.2.2', 'Storage and Disposition of Blinded Investigational Product(s)', '66', '5.5.2.3', 'Preparation/Reconstitution of Dosage Form(s)', '67', '5.5.3', 'Method of Assigning Subjects to Treatment Arms', '67', '5.5.4', 'Selection and Timing of Dose for Each Subject', '68', '5.5.4.1', 'Dosing', '68', '5.5.4.2', 'Dose Modifications', '68', '5.5.4.2.1', 'Dose Treatment Delays due to Toxicity or Progression', '68', '5.5.4.2.2', 'Dose Reduction Guidelines', '69', '5.5.5', 'Blinding', '72', '5.5.5.1', 'Blinding of Investigational Product', '72', '5.5.5.2', 'Blinding of Data for Independent Data Monitoring Committee', '(IDMC)', '72', '5.5.6', 'Treatment Compliance', '72', '5.5.7', 'Drug Accountability', '73', '5.6', 'Discussion and Justification of Study Design', '74', '22']\n\n###\n\n", "completion": "END"}